Xarelto Lawsuit Plaintiffs Note New York Times Article Discussing Potentially Defective Testing Device

March 28, 2016 – – BloodThinnerHelp.com reports on the publication of a New York Times article which discussed an investigation by the U.S. Food and Drug Administration (FDA) into whether a recalled device used during Xarelto clinical testing could have affected the trial results leading up to the drug’s FDA approval in 2011.

In a recent New York Times article, it was noted that the FDA has started to ask Johnson & Johnson (Janssen), “…detailed questions about whether there was evidence that the device was malfunctioning while the trial was underway, according to a legal brief filed in federal court on Monday by lawyers for patients and their families who say they were injured by the drug. The lawyers also cited internal company documents that they said showed doctors were complaining to the trial leadership during the course of the study.”

The New York Times also reported that, “Regulators are looking at whether the malfunctioning device might have led doctors to give patients the wrong dose of warfarin, which could have led to additional bleeding episodes and given an unfair advantage to Xarelto.” It was indicated that Johnson & Johnson (Janssen) and Bayer reportedly, “…notified regulators that the device that was used in the trial had been recalled in 2014 because it was understating patients’ risk of bleeding.”

Since 2011, over just 5 year’s time, Xarelto has become the topic of more than 3,400 lawsuits. Over 2,800 of these complaints were filed in federal courts from across the nation and then transferred and consolidated to a single court in Eastern Louisiana by the U.S. Judicial Panel on Multidistrict Litigation, forming MDL number 2592. Additionally, over 600 Xarelto lawsuit complaints have been consolidated to form a mass tort program in Philadelphia, Pennsylvania by the Court of Common Pleas.

Of these thousands of filed lawsuits, plaintiffs all share similar allegations filed against Xarelto and its manufacturers, Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson corporation). Involved plaintiffs claim that Xarelto puts users at heightened risk for sudden and dangerous bleeding episodes. Some of the plaintiffs involved in current suits, in fact, have filed on behalf of their loved ones who have passed away due to fatal bleeding.

As plaintiffs involved in current Xarelto lawsuits await trial dates, Attorney Joseph Osborne is currently working to help other patients who have used Xarelto and have suffered from adverse events that they believe were caused by the drug. He wants to help ensure that affected patients will be given the critical opportunity to investigate their legal rights in the matter. These individuals may be entitled to substantial compensation through legal action. To better help those wishing to pursue justice, Attorney Osborne is offering complimentary Xarelto consultations for qualified parties at this time.

To obtain additional information, or to ask questions regarding Xarelto bleeding lawsuits, please contact Joseph Osborne, Esq. at (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008911